Live Breaking News & Updates on Total Functional Capacity

Stay updated with breaking news from Total functional capacity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Clinical Challenges: NfL as Emerging Biomarker in Huntington's Disease

Neuron-specific protein might allow for earlier treatment, better prognostication ....

Daniel Claassen , Furr Stimming , Erin Furr Stimming , Vanderbilt University Medical Center , Mcgovern Medical School , Research Utility , Disease Integrated Staging System , Total Functional Capacity , Huntington 039s Disease , Antisense Oligonucleotide , Amyotrophic Lateral Sclerosis ,

First-Ever Huntington Staging System May Spur Drug Development

The first-ever staging system for Huntington disease is a key step toward developing drugs that target the disorder before the onset of debilitating symptoms. ....

United States , New Jersey , Erin Furr Stimming , Cristina Sampaio , Movement Disorder Society , Green Valley Pharmaceuticals , Drug Administration , Gw Pharmaceuticals , Huntington Disease Society Of America Center , Huntington Disease Regulatory Science Consortium , Mcgovern Medical School , Pinteon Pharmaceuticals , Disease Integrated Staging System , Medscape Medical , Disease Regulatory Science Consortium , Independence Scale , Total Functional Capacity , Unified Huntington , Disease Rating , Medscape Medical News , Disease Society , America Center , Critical Path Institute , Kyowa Kirin , Huntington Disease , Huntingtons Disease ,

uniQure (QURE) Provides Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130

uniQure (QURE) Provides Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Ricardo Dolmetsch , Matt Kapusta , Year Observations , Low Dose Cohort , Total Functional Capacity , Total Motor Scores ,

uniQure Announces Update on Low-Dose Cohort in Phase I/II

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean. ....

United States , Noord Holland , Ricardo Dolmetsch , Matt Kapusta , Phasei Ii Clinical Program , Neurofilament Light Chain , Year Observations , Low Dose Cohort , Total Functional Capacity , Total Motor Scores , Conference Call , Qure Conference Call , Nasdaq Qure , Niqure Inc , Mt 130 , Gene Therapy , Untington 39 S , Low Dose Cohort , Huntington 39s Disease ,

uniQure Inc.: uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed ....

United States , Noord Holland , Chiara Russo , Ricardo Dolmetsch , Mariae Cantor , Matt Kapusta , Tom Malone , Phasei Ii Clinical Program , Neurofilament Light Chain , Year Observations , Low Dose Cohort , Total Functional Capacity , Total Motor Scores , Conference Call , Qure Forward Looking , Annual Report , Quarterly Report , Qure Contacts ,